Business Context and Reporting Period
Company: MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.)
Reporting Period: Fiscal Year ended April 30, 2026
Business Model: A Bio-Native AI company combining proprietary biological pattern analysis (HYFT® Technology) with wet-lab capabilities for therapeutic discovery. The company is transitioning from a project-based CRO model to a recurring revenue model via its LensAI® platform and ReefIQ® context layer.
Key Strategic Event: On August 6, 2025, the company divested its Netherlands-based subsidiary (IPA Europe) to AVS Bio for approximately US$12.0 million in enterprise value, generating US$10.3 million in net proceeds. This divestiture is classified as discontinued operations.
Key Financial Metrics (Fiscal 2026)
| Metric | Fiscal 2026 (CAD$) | Fiscal 2025 (CAD$) |
|---|---|---|
| Revenue (Continuing Ops) | 15,558 | 10,626 |
| Gross Profit | 9,148 | 5,731 |
| Gross Margin | 58.8% | 53.9% |
| Net Loss (Continuing Ops) | (15,102) | (33,147) |
| Net Loss (Total) | (13,949) | (30,234) |
| Cash and Cash Equivalents | 11,348 | 10,665 |
| Operating Cash Flow | (12,463) | (6,410) |
| Total Assets | 21,376 | 44,441 |
| Total Liabilities | 9,627 | 20,815 |
Note: All figures are in thousands of Canadian dollars unless otherwise specified. The significant reduction in Total Assets and Liabilities is primarily due to the disposal of the Netherlands subsidiary.
Material Changes vs. Prior Period
- Revenue Growth: Revenue from continuing operations increased 46% to CAD$15.6 million, driven by a 48% increase in project revenue.
- Margin Expansion: Gross margin improved to 58.8% from 53.9%, attributed to improved project revenue mix.
- Expense Reduction: Net loss from continuing operations decreased significantly (from CAD$33.1M to CAD$15.1M). This improvement is largely due to the absence of the CAD$21.2 million impairment charge on intangible assets recorded in Fiscal 2025 related to the BioStrand cash-generating unit.
- Discontinued Operations: The sale of IPA Europe resulted in a net income of CAD$1.2 million from discontinued operations for Fiscal 2026.
- Liquidity: Cash used in operating activities increased to CAD$12.5 million, reflecting higher commercialization and R&D investments, partially offset by the cash proceeds from the divestiture.
Guidance, Outlook, and Risks
Outlook and Strategy: Management is focused on three strategic pillars: (1) building intelligence-driven recurring revenue via LensAI® subscriptions and API integrations; (2) advancing a wholly owned portfolio of AI-designed assets (including GLP-1, Dengue, and Longevity programs); and (3) deepening multi-year enterprise partnerships. The company recently launched ReefIQ® as a biological context layer for AI drug discovery.
Going Concern Warning: The filing explicitly states that the company does not have sufficient cash reserves to fund operations for the next twelve months. This raises substantial doubt about the company's ability to continue as a going concern. The company's ability to continue depends on obtaining additional financing and generating sufficient revenues.
Material Weakness in Internal Controls: Management identified a material weakness in internal control over financial reporting, specifically a lack of sufficient resources to address complex technical accounting issues. This weakness remains unremediated as of April 30, 2026.
Key Risks:
- Financing Risk: Negative operating cash flows and the need for additional capital to fund R&D and commercialization.
- Regulatory/Compliance: Risks associated with evolving AI regulations, data privacy (GDPR/CCPA), and cybersecurity threats.
- Market Adoption: Uncertainty regarding the speed of market adoption for AI-based and SaaS-based tools in drug discovery.
- Listing Compliance: The company previously faced Nasdaq minimum bid price non-compliance but regained compliance in July 2025.
Investor Verification Checklist
- Capital Adequacy: Verify the status of the new "Jones ATM Facility" (US$30M capacity) and any subsequent equity issuances to determine if the going concern risk has been mitigated.
- Internal Controls: Review the progress of remediation efforts for the material weakness in internal controls over financial reporting.
- Revenue Quality: Analyze the composition of revenue to confirm the shift from project-based work to recurring subscription revenue (LensAI®/ReefIQ®).
- Asset Pipeline: Validate the progress of internal AI-driven programs (GLP-1, Dengue, Longevity) and any potential licensing or partnership deals.
- Shareholder Dilution: Monitor the volume of shares sold under the ATM facility and the impact on existing shareholders.